FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519380605> ?p ?o ?g. }

• W2519380605 endingPage "1064" @default.
• W2519380605 startingPage "1064" @default.
• W2519380605 abstract "1064 Background: Trastuzumab (T) is an important part of therapy for patients diagnosed with MBC who are HER2-positive. Approximately one third of these patients develop CNS metastases. The impact of CNS metastases on T use and survival in elderly patients has not been described. Methods: We used SEER-Medicare data to examine associations between diagnosis of CNS metastases, treatment, and survival, in a cohort of women who first received T following diagnosis of MBC. Medicare claims were used to identify T, chemotherapy, and diagnosis of CNS and other types of metastases. Patients were included if their first Medicare claim for T was between January 1, 2000 and December 31, 2006. Patients were excluded if they were diagnosed with CNS metastases prior to beginning T. They were followed from the start of T until death or the end of their claims. Multivariate analyses were performed to identify the associations between diagnosis of CNS metastases and (A) permanent discontinuation of T, and (B) all-cause mortality. Permanent discontinuation was defined as two or more months in a row prior to death or censoring with no claim for T. Results: 651 patients met the eligibility criteria. The mean age was 76 years, 422 (65%) were diagnosed with stage 0-III disease and had a distant recurrence, while the remainder were diagnosed with de novo stage IV disease. The mean duration of follow-up was 37 months, and 133 (20%) were diagnosed with CNS metastases during this interval. In multivariate analysis, diagnosis of CNS metastases (HR 2.11; p <0.001), age ≥ 80 (HR 1.65; p=0.004), and hospitalization (HR 1.89; p <0.001) all were associated with higher rates of discontinuing T. In multivariate survival analysis, diagnosis of CNS metastases (HR 3.60; p <0.001), discontinuing T (HR 3.35; p <0.001), discontinuing or not having had other chemotherapy (HR 2.48; p <0.001), and de novo stage IV disease (HR 1.32; p =0.03) were associated with higher mortality rates. Diagnosis of other metastases did not affect mortality. Conclusions: Although causality cannot be determined, there appears to be an association between diagnosis of CNS metastases and discontinuation of T, and also between discontinuation of therapy, including T, and survival. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech" @default.
• W2519380605 created "2016-09-23" @default.
• W2519380605 creator A5000305488 @default.
• W2519380605 creator A5013948318 @default.
• W2519380605 creator A5018773741 @default.
• W2519380605 creator A5019132733 @default.
• W2519380605 creator A5021458679 @default.
• W2519380605 creator A5072015843 @default.
• W2519380605 date "2010-05-20" @default.
• W2519380605 modified "2023-09-27" @default.
• W2519380605 title "Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC)." @default.
• W2519380605 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.1064" @default.
• W2519380605 hasPublicationYear "2010" @default.
• W2519380605 type Work @default.
• W2519380605 sameAs 2519380605 @default.
• W2519380605 citedByCount "0" @default.
• W2519380605 crossrefType "journal-article" @default.
• W2519380605 hasAuthorship W2519380605A5000305488 @default.
• W2519380605 hasAuthorship W2519380605A5013948318 @default.
• W2519380605 hasAuthorship W2519380605A5018773741 @default.
• W2519380605 hasAuthorship W2519380605A5019132733 @default.
• W2519380605 hasAuthorship W2519380605A5021458679 @default.
• W2519380605 hasAuthorship W2519380605A5072015843 @default.
• W2519380605 hasConcept C121608353 @default.
• W2519380605 hasConcept C126322002 @default.
• W2519380605 hasConcept C141071460 @default.
• W2519380605 hasConcept C143998085 @default.
• W2519380605 hasConcept C146357865 @default.
• W2519380605 hasConcept C151730666 @default.
• W2519380605 hasConcept C2775930923 @default.
• W2519380605 hasConcept C2776694085 @default.
• W2519380605 hasConcept C2778715236 @default.
• W2519380605 hasConcept C2779134260 @default.
• W2519380605 hasConcept C2779786085 @default.
• W2519380605 hasConcept C38180746 @default.
• W2519380605 hasConcept C530470458 @default.
• W2519380605 hasConcept C71924100 @default.
• W2519380605 hasConcept C72563966 @default.
• W2519380605 hasConcept C86803240 @default.
• W2519380605 hasConceptScore W2519380605C121608353 @default.
• W2519380605 hasConceptScore W2519380605C126322002 @default.
• W2519380605 hasConceptScore W2519380605C141071460 @default.
• W2519380605 hasConceptScore W2519380605C143998085 @default.
• W2519380605 hasConceptScore W2519380605C146357865 @default.
• W2519380605 hasConceptScore W2519380605C151730666 @default.
• W2519380605 hasConceptScore W2519380605C2775930923 @default.
• W2519380605 hasConceptScore W2519380605C2776694085 @default.
• W2519380605 hasConceptScore W2519380605C2778715236 @default.
• W2519380605 hasConceptScore W2519380605C2779134260 @default.
• W2519380605 hasConceptScore W2519380605C2779786085 @default.
• W2519380605 hasConceptScore W2519380605C38180746 @default.
• W2519380605 hasConceptScore W2519380605C530470458 @default.
• W2519380605 hasConceptScore W2519380605C71924100 @default.
• W2519380605 hasConceptScore W2519380605C72563966 @default.
• W2519380605 hasConceptScore W2519380605C86803240 @default.
• W2519380605 hasIssue "15_suppl" @default.
• W2519380605 hasLocation W25193806051 @default.
• W2519380605 hasOpenAccess W2519380605 @default.
• W2519380605 hasPrimaryLocation W25193806051 @default.
• W2519380605 hasRelatedWork W1973483870 @default.
• W2519380605 hasRelatedWork W2023654245 @default.
• W2519380605 hasRelatedWork W2030434439 @default.
• W2519380605 hasRelatedWork W2069175206 @default.
• W2519380605 hasRelatedWork W2092771806 @default.
• W2519380605 hasRelatedWork W2143625559 @default.
• W2519380605 hasRelatedWork W2218005127 @default.
• W2519380605 hasRelatedWork W2937445726 @default.
• W2519380605 hasRelatedWork W2969515167 @default.
• W2519380605 hasRelatedWork W4308928397 @default.
• W2519380605 hasVolume "28" @default.
• W2519380605 isParatext "false" @default.
• W2519380605 isRetracted "false" @default.
• W2519380605 magId "2519380605" @default.
• W2519380605 workType "article" @default.